Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
18M
-
Shares change
-
+4.44M
-
Total reported value, excl. options
-
$635M
-
Value change
-
+$202M
-
Put/Call ratio
-
3.41
-
Number of buys
-
75
-
Number of sells
-
-39
-
Price
-
$35.31
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2017
146 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2017.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18M shares
of 207M outstanding shares and own 8.67% of the company stock.
Largest 10 shareholders include Pentwater Capital Management LP (1.84M shares), BB BIOTECH AG (1.41M shares), FMR LLC (1.31M shares), BlackRock Inc. (1.28M shares), Boxer Capital, LLC (1.28M shares), CREDIT SUISSE AG/ (879K shares), Aisling Capital LLC (837K shares), PINNACLE ASSOCIATES LTD (771K shares), WASATCH ADVISORS INC (767K shares), and VANGUARD GROUP INC (724K shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.